Rapid viral control in a world that needs it. ExeVir develops single-domain antibody-based therapies that help patients ward off viral infections. Our lead drug candidate is in accelerated development as a COVID-19 therapeutic.
Location: Belgium, East Flanders, Ghent
Total raised: $155.46M
Investors 4
| Date | Name | Website |
| - | Fund+ | fundplus.b... |
| - | UCB Ventur... | ucbventure... |
| - | V-Bio Vent... | v-bio.vent... |
| - | SFPIM | sfpim.be |
Funding Rounds 5
| Date | Series | Amount | Investors |
| 28.06.2023 | Grant | $1.75M | - |
| 09.01.2023 | - | $26.71M | - |
| 24.05.2021 | Series A | $50M | - |
| 16.03.2021 | Series A | $50M | - |
| 28.07.2020 | Series A | $27M | - |
Mentions in press and media 17
| Date | Title | Description |
| 18.11.2024 | ExeVir Announces Michael Garrett as New CEO | ExeVir Bio, a Ghent, Belgium-based biotech company developing heavy chain-only antibodies targeting highly conserved epitopes for broad protection against infectious diseases, announced the appointment of Michael Garrett as its new Chief Ex... |
| 28.06.2023 | ExeVir Bio Nets €1.6M Grant in Push to Pioneer Virus-Thwarting Therapies | Key Takeaways: Belgium-based ExeVir Bio has raised €1.6 million in grant funding. The round was led by Flanders Innovation and Entrepreneurship (VLAIO). ExeVir Bio develops single-domain antibody-based therapies to combat viral infections. ... |
| 28.06.2023 | ExeVir Bio Awarded EUR 1.6m Grant for Dengue Research | - |
| 06.04.2023 | Nona Biosciences Enters into Collaboration Agreement with ExeVir Bio | CAMBRIDGE, Mass., April 6, 2023 /PRNewswire/ -- Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited, committed to cutting-edge technology innovation and provider of integrated solutions from "Idea to IND" (I to I™ ... |
| 06.04.2023 | Nona Biosciences Enters into Collaboration Agreement with ExeVir Bio | CAMBRIDGE, Mass., April 5, 2023 /PRNewswire/ -- Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited, committed to cutting-edge technology innovation and provider of integrated solutions from "Idea to IND" (I to I™ ... |
| 13.03.2023 | ExeVir Bio and VIB Announce Data on a New Therapy for Prevention and Treatment for COVID-19. | Ghent, Belgium, 13 March 2023: ExeVir Bio, a biotech company developing robust single domain antibody therapies for broad protection against infectious diseases, and its scientific founders at Belgium’s VIB, Flanders’ leading life sciences ... |
| 09.01.2023 | Belgium’s ExeVir raises €25M from EIB to develop novel COVID-19 therapeutic | Belgium-based ExeVir Bio, a clinical-stage biotechnology company developing nanobody-based therapeutics for infectious diseases, announced on Monday that it has raised €25M in venture debt from The European Investment Bank (EIB). The fundin... |
| 09.01.2023 | ExeVir Bio Secures EUR 25M Venture Debt Financing | ExeVir Bio, a Ghent, Belgium-based biotech company developing nanobody therapies for broad protection against infectious diseases, raised €25M in Venture Debt financing. European Investment Bank provided the loan. The company intends to use... |
| 09.01.2023 | ExeVir Bio secures EUR 25 million venture debt financing from the European Investment Bank | - |
| 20.10.2022 | ExeVir Bio Forges Ahead with Unique Next Generation COVID-19 Therapy and Appoints Dr. Jeanne Bolger as Chair of the Board of Directors | Targeting final lead therapy selection, neutralizing all known previous and current SARS-CoV2 variants of concern by end 2022 |
Show more